TORONTO, ON / ACCESSWIRE / November 10, 2015 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV: TLT) (PINKSHEETS: TLTFF), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that its latest anti-cancer technology research, combining Photo Dynamic Compounds ("PDCs") with laser light to destroy cancer targets was recently presented at the 28th International Congress of Laser Medicine, Laser Florence 2015 from November 5th to 7th, 2015 and was the recipient of the best presentation award.
The research entitled, "A Novel Family of Osmium Complex Photosensitizers for Multi-Wavelength Photo Dynamic Therapy ("PDT")" conducted in collaboration between the Department of Medical Biophysics, University of Toronto, the Department of Chemistry, Acadia University and Theralase provided evidence that Theralase's Osmium based PDCs when activated with various wavelengths of light were able to effectively destroy cancerous targets, pre-clinically.
The research will be published by Medimond S.R.L. under their Monduzzi Editore International Proceedings Division, a leading international scientific academic publisher based in Bologna, Italy.
PDT combines light, oxygen and a PDC to cause the accumulation of cytotoxic Reactive Oxygen Species ("ROS") inside a cell resulting in localized cell death. To fully realize the potential of PDT, PDCs with favourable physical, chemical and biological properties are required to achieve maximum selectivity and efficacy.
The collaborative research demonstrated that three of the Company's tunable Osmium (II) biquinoline-based PDCs were able to absorb light at wavelengths throughout the green, red, and near infrared spectrum, allowing selective activation to destroy cancerous targets in a wide range of tissue depths ranging from thousands of an inch to inches.
In-vitro (Petri dish) and in-vivo (animal model) PDT using these three PDCs was successful in these wavelength ranges providing similar efficacy and immune mediated responses as Theralase's Ruthenium based PDCs, allowing the potential to destroy the primary tumour and prevent recurrence.
These findings suggest that this family of Osmium-based PDCs are potent PDT agents for the oncological treatment of solid tumors.
Roger Dumoulin-White, President and CEO, Theralase stated that, "The presentation of Theralase's latest research at international congresses and subsequent publication in international journals allows the Company to validate its technology against international competition and exemplifies the significance of this scientific work. Theralase is awaiting Health Canada and Food and Drug Administration ("FDA") approval of its TLC-3000 anti-cancer technology to commence enrolling patients in late 4Q2015 in either Canada, the United States of America or both to determine the safety, tolerability and efficacy of this technology in the destruction of Non-Muscle Invasive Bladder Cancer."
About Theralase Technologies Inc.
Theralase Technologies Inc. ("Theralase(R)") (TSXV: TLT) (PINKSHEETS: TLTFF) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase's Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
SOURCE: Theralase Technologies Inc.